巨块型肝癌介入灌注康莱特治疗的临床研究

Clinical Observation on Interventional Infusion of Kanglaite on Massive Liver Cancer

目的观察巨块型肝癌介入灌注康莱特的临床效果。方法随机选取2012年5月—2014年5月我院收治的巨块型肝癌患者60例,依据治疗方法将患者分为介入灌注单独化疗药物组(单独组)和介入灌注化疗药物联合康莱特组(联合组)各30例,统计分析两组临床疗效、毒副反应发生情况及1年、2年、3年生存情况。结果联合组患者的总缓解率(40.0%)显著高于单独组(23.3%)(P<0.05);联合组血小板减少、白细胞减少、肝功能损害发生率分别为13.3%、46.7%、23.3%均显著低于单独组的43.3%、73.3%、36.7%(P<0.05);联合组1年、2年、3年生存率分别为83.3%、53.3%、30.0%均显著高于单独组的66.7%、33.3%、6.7%(P<0.05)。结论巨块型肝癌介入联合灌注化疗及康莱特较单独灌注化疗药物临床效果好。

Objective To observe the clinical effect of interventional infusion of Kanglaite(KLT) on massive liver cancer.Methods 60 cases of patients with massive liver cancer were randomly divided into interventional infusion chemotherapy drug alone group(alone group) and interventional chemotherapy combined with Kanglaite group(combination group),30 cases in each group. The efficacies and incidences of toxicity,1 year,2-year and 3-year survival rates of the two groups were statistically analyzed. Results The total remission rate of combination group was 40.0%,significantly higher than 23.3% of alone group(P<0.05),the thrombocytopenia,leukopenia,liver function damage rates of combination group were 13.3%,46.7%,23.3%,significantly lower than 43.3%,73.3%,36.7% of alone group(P<0.05),the 1 year,2-year,3-year survival rates of combination group were 83.3%,53.3%,30.0%,significantly higher than 66.7%,33.3%,6.7% of alone group(P<0.05). Conclusion The clinical effect of interventional infusion chemotherapy and of KLT of massive liver cancer is better than infusion of individual drugs.